Skip to main content
Premium Trial:

Request an Annual Quote

Twist Bioscience Announces $100M Public Stock Offering

NEW YORK – Twist Bioscience said Tuesday after the close of the market that it intends to sell up to $100 million of its common stock in an underwritten public offering.

Twist said it plans to use the proceeds to invest in its research and development organization, including pharmaceutical biologics drug discovery and DNA data storage; to scale its next-generation sequencing commercial operations; and to expand its production capacity. The company will also use the funds for working capital and general corporate purposes. 

JP Morgan, Cowen, and Evercore Group are acting as joint book-running managers and Robert W. Baird as lead manager.

In December, Twist entered into an agreement with Cowen to sell up to $50 million in stock, following a shelf registration filed with the US Securities and Exchange Commission in November. Twist also completed an offering of approximately 2.2 million shares of common stock in January, raising about $48.2 million. The company went public in October 2018 with an initial $86.3 million offering and raised an additional $84 million in May 2019. 

Twist intends to grant the underwriters a 30-day option to purchase up to $15 million worth of its common stock.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.